"To progress all together against cancer"
As an oncology focused company, CIPREVO has patented its proprietary first-in-class drug-drug conjugates to treat patients with recurrent and/or metastatic solid tumors. The first drug-drug conjugate candidate of our pipeline is an antiproliferative agent which has demonstrated activity over a large spectrum of experimental cancer models. The in vivo proof of concept demonstrating antitumor efficacy has been validated in animal models bearing human tumors with a high medical need including Small Cell Lung Cancer.
CIPREVO based on this original approach is building a robust portfolio of medicines in collaboration with academic and private partners to bring innovative solutions to patients with advanced cancers.
CIPREVO is open to discuss the clinical development of the most advanced drug candidates.
Babae N, Bourajjaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH, Van Haastert RJ, Yousefi A, Mastrobattista E, Storm G, Berezikov E, Cuppen E, Woodle M, Schaapveld RQ, Prevost GP, Griffioen AW, Van Noort PI, Schiffelers RM.
Oncotarget. 2014 Aug 30;5(16):6687-700.
Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C.
Clin Cancer Res. 2012 Oct 1;18(19):5314-28. doi: 10.1158/1078-0432.CCR-12-0372. Epub 2012 Jul 23.
J Biol Chem. 2009 Oct 16;284(42):29136-45. doi: 10.1074/jbc.M109.042333. Epub 2009 Jul 31.
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers
Michèle Sabbah, Shahin Emami, Gérard Redeuilh, Sylvia Julien, Grégoire Prévost, Amazia Zimbera, Radia Ouelaaa, Marc Bracke, Olivier De Weverab, Christian Gespachab
Drug Resistance Updates Volume 11, Issues 4–5, August–October 2008, Pages 123-151
Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex
Prévost GP, Lonchampt MO, Holbeck S, Attoub S, Zaharevitz D, Alley M, Wright J, Brezak MC, Coulomb H, Savola A, Huchet M, Chaumeron S, Nguyen QD, Forgez P, Bruyneel E, Bracke M, Ferrandis E, Roubert P, Demarquay D, Gespach C, Kasprzyk PG.
Cancer Res. 2006 Sep 15;66(18):9227-34.
Find representative publications from CIPREVO below. Additionnal ones are available on Google scholar.
​
​